Cytokinetics Inc (CYTK)

Current ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Total current assets	US$ in thousands	628,051	561,416	586,575	680,629	795,186	884,275	602,250	623,526	535,672	494,941	364,229	433,117	474,221	418,412	218,954	225,938	233,752	176,535	184,951	186,400
Total current liabilities	US$ in thousands	102,678	77,723	65,617	75,220	84,617	76,496	66,843	66,847	71,860	80,868	61,766	35,930	31,199	27,573	22,696	20,741	26,023	21,517	21,959	26,277
Current ratio		6.12	7.22	8.94	9.05	9.40	11.56	9.01	9.33	7.45	6.12	5.90	12.05	15.20	15.17	9.65	10.89	8.98	8.20	8.42	7.09

December 31, 2023 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $628,051K ÷ $102,678K
= 6.12

The current ratio of Cytokinetics Inc has shown a decreasing trend over the past several quarters, from 11.56 in Q3 2022 to 6.12 in Q4 2023. This indicates that the company's current assets may not be as sufficient to cover its current liabilities in the most recent quarter. However, it is worth noting that the current ratio has been above 1.0 in all quarters, suggesting that the company still has more current assets than current liabilities overall.

The significant drop in the current ratio from Q3 2022 to Q4 2023 may raise some concerns about the company's liquidity position. Investors and creditors may pay closer attention to how efficiently Cytokinetics manages its current assets and liabilities going forward to ensure that it can meet its short-term obligations. Overall, while the current ratio has fluctuated, it remains above 1.0 in all quarters, indicating that the company has the potential to meet its short-term obligations.